Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPOLIS: Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Recurrent/Persistent HNSCC
NCT07195734Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2026
- Primary completion
- Feb 2033
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab, carboplatin, Paclitaxel Micelles for Injection in squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Started Apr 2026; status: recruiting.
02
Drugs
cemiplimabcarboplatinPaclitaxel Micelles for Injection
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT07195734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195734.